ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease

Alzheimer’s disease (AD) is an age-related neurodegenerative disease that affects 50 million people worldwide, with 10 million new cases occurring each year. The emotional and economic impacts of AD on patients and families are devastating. Approved treatments confer modest improvement in symptoms,...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Grant A. Krafft, Jasna Jerecic, Eric Siemers, Erika N. Cline
Format:	Artigo
Język:	Inglês
Wydane:	Frontiers Media S.A. 2022-04-01
Seria:	Frontiers in Neuroscience
Hasła przedmiotowe:	Alzheimer’s disease immunotherapy oligomer-selective therapeutic antibody AβO = amyloid beta oligomer synaptic plasticity
Dostęp online:	https://www.frontiersin.org/articles/10.3389/fnins.2022.848215/full
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!